publications-banner

Information about pipeline products

PublicationView

Dato-DXd
Lung Cancer
Datopotamab deruxtecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer: The randomized, open-label phase III TROPION-Lung01 study
Ahn M-J, Tanaka K, Paz-Ares L, et al.
J Clin Oncol. 2024:JCO2401544. doi: 10.1200/JCO-24-01544. Epub ahead of print.
T-DXd
Breast Cancer
A pooled analysis of trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer with brain metastases
André F, Cortés J, Curigliano G, et al.
Ann Oncol. 2024:S0923-7534(24)03928-0. doi: 10.1016/j.annonc.2024.08.2347. Epub ahead of print.
T-DXd
Breast Cancer
Trastuzumab deruxtecan for the treatment of patients with HER2-positive breast cancer with brain and/or leptomeningeal metastases: an updated overall survival analysis using data from a multicenter retrospective study (ROSET-BM)
Nakayama T, Niikura N, Yamanaka T, et al.
Breast Cancer. 2024;31(6):1167-1175. doi: 10.1007/s12282-024-01614-1. Epub 2024.
T-DXd
Colorectal Cancer
Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): Primary results from a multicentre, randomised, phase 2 trial
Raghav K, Siena S, Takashima A, et al.
Lancet Oncol. 2024;25(9):1147-1162. doi: 10.1016/S1470-2045(24)00380-2. Epub 2024.
Valemetostat
Other/Multi
Population pharmacokinetics of total and unbound valemetostat and platelet dynamics in healthy volunteers and patients with non-Hodgkin lymphoma
Fukae M, Baron K, Tachibana M, Mondick J, Shimizu T.
CPT Pharmacometrics Syst Pharmacol. 2024(10):1641-1654. doi: 10.1002/psp4.13201. Epub 2024.
Pexidartinib
Other/Multi
TURALIO® Risk Evaluation and Mitigation Strategy Program (tREMS): 3-year retrospective hepatic safety assessment
Dharmani C, Fofah O, Fallon M, Rajper AW, Wooddell M, Salas M.
Future Oncol. 2024. doi: 10.1080/14796694.2024.2373687. Epub ahead of print.
T-DXd
Breast Cancer
Concurrent use of trastuzumab deruxtecan and radiation therapy in HER2-positive and HER2-low metastatic breast cancer: A single-center experience and review of the literature.
Bouziane J, Loap P, Cao K, et al.
Am J Clin Oncol. 2024. doi: 10.1097/COC.0000000000001135. Epub ahead of print.
HER3-DXd
Breast Cancer
Patritumab deruxtecan in HER2-negative breast cancer: Part B results of the window-of-opportunity SOLTI-1805 TOT-HER3 trial and biological determinants of early response
Brasó-Maristany F, Ferrero-Cafiero JM, Falato C, et al.
Nat Commun. 2024;15(1):5826. doi: 10.1038/s41467-024-50056-y.
T-DXd
Breast Cancer
Trastuzumab deruxtecan versus trastuzumab emtansine in Asian patients with HER2-positive metastatic breast cancer
Iwata H, Xu B, Kim S-B, et al.
Cancer Sci. 2024;115(9):3079-3088. doi: 10.1111/cas.16234. Epub 2024 Jul 9.
HER3-DXd
Lung Cancer
Real-world treatment patterns and clinical outcomes among patients with metastatic or unresectable EGFR-mutated non-small cell lung cancer previously treated with osimertinib and platinum-based chemotherapy
Patel J, Meng J, Le H, et al.
Adv Ther. 2024;41(8):3299-3315. doi: 10.1007/s12325-024-02936-4. Epub 2024.
Pages: 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  

footer